Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| INHIBITOR | Complement C5 inhibitor | PMC |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Granulomatosis with Polyangiitis | 2 | D014890 | ClinicalTrials |
| Shock, Septic | 2 | D012772 | ClinicalTrials |
| Hidradenitis Suppurativa | 2 | D017497 | ClinicalTrials |
| Microscopic Polyangiitis | 2 | D055953 | ClinicalTrials |
| Pyoderma | 2 | D011711 | ClinicalTrials |
| Sepsis | 2 | D018805 | ClinicalTrials |
| Inflammation | 2 | D007249 | ClinicalTrials |
| Scleroderma, Systemic | 2 | D012595 | ClinicalTrials |
| Severe Acute Respiratory Syndrome | 2 | D045169 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| ChEMBL | CHEMBL2109636 |
CONTENTS